Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer-Reference-Cited by-同舟云学术

Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer

Published:2022-07-04 Issue:8 Volume:22 Page:861-874
ISSN:1473-7140
Container-title:Expert Review of Anticancer Therapy
language:en
Short-container-title:Expert Review of Anticancer Therapy

Author:

Issa Majd¹^ORCID,Tang Joy¹,Guo Yizhen²,Coss Chris²,Mace Thomas A.³,Bischof Jason⁴,Phelps Mitch²,Presley Carolyn J¹^ORCID,Owen Dwight H¹

Affiliation:

1. Division of Medical Oncology, Department of Internal Medicine, the Ohio State University Wexner Medical Center – Comprehensive Cancer Center, Columbus, USA

2. College of Pharmacy, the Ohio State University Wexner Medical Center – Comprehensive Cancer Center, Columbus, USA

3. Division of Gastroenterology, Hepatology & Nutrition, Department of Internal Medicine, the Ohio State University Wexner Medical Center, Columbus, USA

4. Department of Emergency Medicine, the Ohio State University Wexner Medical Center – Comprehensive Cancer Center, Columbus, USA

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737140.2022.2094772

Reference190 articles.

1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

2. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

3. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer

4. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer

5. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Association of Immune-Related Adverse Events with the Efficacy of Atezolizumab in Previously Treated Advanced Non-Small-Cell Lung Cancer Patients: A Single-Center Experience;Cancers;2024-08-28

2. Toxicity in the era of immune checkpoint inhibitor therapy;Frontiers in Immunology;2024-08-23

3. Diagnosis and management of immune mediated liver injury from checkpoint inhibitors;Current Opinion in Gastroenterology;2024-02-15

4. Challenges in Management of Immune Checkpoint Inhibitor-Associated Hepatitis;EMJ Gastroenterology;2023-10-06

5. Challenges in Management of Immune Checkpoint Inhibitor-Associated Hepatitis;EMJ Gastroenterology;2023-10-06